سعر مارفيتنس 20/5/12.5مجم 30 قرص 2024

Olmesartan 20 mg / amlodipine 5 mg / hydrochlorothiazide 12.5 mg film-coated tablets, pack of 30 (3 strips of 10).

• Treatment of hypertension, to lower blood pressure; not indicated for initial therapy.Population: AdultsDailyMed (U.S. National Library of Medicine)

• Most common adverse reactions (incidence 2% or more): dizziness, peripheral oedema, headache, fatigue, nasopharyngitis, muscle spasms, nausea, upper respiratory tract infection, diarrhoea, urinary tract infection and joint swelling.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Anuria.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hypersensitivity to any component or to other sulfonamide-derived drugs.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Do not co-administer aliskiren in patients with diabetes.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Fetal toxicity (boxed warning): discontinue as soon as possible when pregnancy is detected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hypotension: correct volume or salt depletion before administration.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Increased angina or myocardial infarction may occur on starting or increasing the dose of a calcium channel blocker, particularly in patients with severe obstructive coronary artery disease.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• NSAIDs including selective COX-2 inhibitorsMay increase the risk of renal impairment and reduce the antihypertensive effect; NSAIDs can also reduce the diuretic and natriuretic effects of thiazides.DailyMed (U.S. National Library of Medicine)
• Dual RAS blockade (ACE inhibitors, other ARBs, aliskiren)Increased risk of renal impairment, hypotension and hyperkalaemia; do not use aliskiren with this product in patients with diabetes.DailyMed (U.S. National Library of Medicine)
• ColesevelamConsider administering olmesartan at least 4 hours before colesevelam.DailyMed (U.S. National Library of Medicine)

• Can cause fetal harm (boxed warning): drugs acting on the renin-angiotensin system during the second and third trimesters reduce fetal renal function and increase fetal and neonatal morbidity and death; discontinue as soon as possible when pregnancy is detected.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Amlodipine and hydrochlorothiazide are present in human milk and olmesartan in rat milk; breastfeeding is not recommended during treatment.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Olmesartan: Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking its binding to the AT1 receptor.
• Amlodipine: Inhibits transmembrane calcium influx into vascular smooth muscle and cardiac muscle; peripheral arterial vasodilator.
• Hydrochlorothiazide: Promotes renal excretion of sodium and chloride, reducing intravascular volume.